Children 's Oncology Group ( COG ) AALL0434 is a Phase III study designed to test the safety and efficacy of nelarabine when incorporated into a COG augmented BFM-based regimen , which increases exposure to agents with potential neurotoxicity compared to the historical AALL00P2 regimen .